SUMMARY ANSWER: Addition of ET-1 to the medium in which human germinal vesicle (GV)-stage immature oocytes are cultured enhances the GV breakdown (GVBD) rate; the resumption of meiosis may be initiated by ET-1 downregulating the expression of connexin-26 (Cx26) in cumulus cells via endothelin receptor type B (ETRB), leading to decreased cAMP levels in the oocyte.
Introduction
In-vitro maturation (IVM), a technique derived from assisted reproduction technology, has emerged over the last 20 years as a strategic infertility treatment option. IVM was initially proposed for women at risk of ovarian hyper-stimulation syndrome (OHSS), but is now also used to preserve the fertility of young women with cancer by salvaging immature oocytes collected via standard IVF/ICSI and to provide a non-stimulation-based method for oocyte donors (Grynberg et al., 2013) . However, although IVM is widely used, the maturation rates of oocytes and subsequent developmental potential of embryos generated using this technique are significantly lower than those of oocytes matured in vivo, and the pregnancy rates of IVM cycles are lower than those of routine IVF/ICSI cycles. In other words, IVM procedures are not as effective as IVF procedures, and IVM culture technology requires improvement (Practice Committees of the American Society for Reproductive and the Society for Assisted Reproductive, 2013) .
In mammals, oocytes remain in a dormant state (diplotene stage of prophase I) until just before ovulation. In oocytes arrested at the late prophase stage, a pre-ovulatory surge of luteinizing hormone (LH) triggers the resumption of meiosis which is characterised by germinal vesicle breakdown (GVBD), chromosome condensation, and extrusion of the first polar body in preparation for fertilisation and early embryonic development. However, oocytes express few or no LH receptors and are insensitive to direct LH stimulation. Thus, cell factors released by cumulus and granulosa cells are expected to convey the LH stimuli to oocytes. Parker et al. demonstrated that the resumption of meiosis in oocytes depends on the production of epidermal growth factor (EGF)-like proteins by granulosa cells. These EGF-related growth factors serve as paracrine mediators to propagate LH signals throughout the follicle (Park et al., 2004) . In a previous study, we demonstrated that like EGF-related growth factors, endothelin-1 (ET-1) is a paracrine factor secreted by ovarian somatic cells in pre-ovulatory follicles and it regulates oocyte maturation in mice .
ET-1, a member of the endothelin family, was initially identified as a vasoconstrictor. Endothelins have been shown to play important regulatory roles in various physiological processes, including cardiovascular disorders, pulmonary disease, and renal disease (Khimji and Rockey, 2010) . The biological effects of ET-1 are mediated by two G-proteincoupled receptors, endothelin receptors type A (ETRA) and type B (ETRB) (Meidan and Levy, 2007) . Recent studies have identified endothelins as local regulators that can modulate multiple cyclic events in the ovary, including follicle growth, steroidogenesis, oocyte maturation, ovulation, corpus luteum formation, and luteolysis (Bridges et al., 2011; Ko et al., 2012) . ET-1 is expressed in the cytoplasm of human granulosa cells (Magini et al., 1996) , and the concentration of ET-1 in follicular fluid correlates negatively with the IVF pregnancy rate (Zhao et al., 2010) . A microarray analysis has also revealed a significant increase in ET-1 transcript expression in the mouse ovary after stimulation with human chorionic gonadotropin (hCG). In addition, ET-1 can induce GVBD in mouse pre-ovulatory follicles via a process mediated by cumulus cells ). However, whether or not ET-1 induces the resumption of meiosis in humans, and the effects of ET-1 on IVM, remain unknown.
Accordingly, in this study we demonstrated that ET-1 treatment promotes human oocyte maturation through a process mediated by the downregulation of the gap junction protein connexin 26 (Cx26) in cumulus cells.
Materials and methods

Patients and oocyte retrieval
The current study was approved by the medical ethics committee of Women's Hospital, Zhejiang University School of Medicine, and informed consent was obtained from all participants. GV-stage human oocytes were collected from patients who underwent ICSI cycles in our ART unit between December 2014 and February 2016. Ovarian stimulation was performed using a previously described GnRH agonist protocol (Ye et al., 2012) . Ultrasound-guided transvaginal oocyte retrieval was performed 36 h after injection with hCG (Pregnyl, Merck). After three washes with G-MOPS (Vitrolife), the retrieved cumulus-oocyte complex (COC) was cultured in G-IVF (Vitrolife) medium supplemented with 3% serum substitute supplement (SSS).
In-vitro maturation of GV-stage oocytes and embryo culture During oocyte retrieval, we poured the flushing fluid containing the COC into a 100-mm culture dish (Falcon, BD) which was carefully tilted to expand the COC. Subsequently, GV-stage COCs could be easily identified under a stereomicroscope and separated from mature oocytes. Sibling GV-stage COCs with similar sizes, appearances and cumulus statuses were randomly allocated into four groups (70 oocytes/group): (1) GV-stage oocytes with cumulus cells, cultured with ET-1 (100 ng/ml, Tocris Bioscience); (2) GV-stage oocytes with cumulus cells, cultured without ET-1; (3) GV-stage oocytes denuded of cumulus cells by hyaluronidase (Vitrolife), cultured with ET-1 and (4) GV-stage oocytes denuded of cumulus cells, cultured without ET-1. After incubation at 37°C in a controlled atmosphere (6% CO 2 ) for 24 h, the remaining cumulus cells were denuded from GV-stage oocytes, and oocyte maturity was evaluated. Oocytes without first polar bodies were considered immature and classified as GV stage or metaphase I (MI) stage according to the presence of a GV. Oocytes exhibiting extrusion of the first polar body (MII stage) were fertilised using sperm with normal parameters by ICSI. At 16-18 h after microinjection, the zygotes were screened to assess fertilisation (two pronuclei). Embryos were then cultured to the blastocyst stage (5-6 days).
Cumulus cell culture
Cumulus cells were denuded from oocytes using hyaluronidase (Vitrolife). After three washes with D-phosphate-buffered saline (PBS), the cumulus cells were inoculated in a 35-mm culture dish (Falcon, BD) and cultured in minimum essential medium alpha (α-MEM) (Invitrogen) with or without 100 ng/ml ET-1. Additionally, some cumulus cells were cultured with 100 ng/ml ET-1 with or without 1 μM BQ-123 (Sigma-Aldrich) or 1 μM BQ-788 (Sigma-Aldrich).
Hormone testing
Approximately 1 × 10 6 cumulus cells were pre-cultured in serum-free α-MEM for 4 h, followed by culture in α-MEM supplemented with 3% SSS and 100 ng/ml ET-1. After 9, 18 and 27 h of treatment with ET-1, the culture supernatants were collected and centrifuged at 200g for 10 min, aspirated, and stored at −80°C until analysis. Chemiluminescence immunisation (Beckman Access Health Company) was used to measure the levels of FSH, LH, and oestradiol (E 2 ).
Extraction of RNA from cumulus cells and real-time RT-PCR
To determine the expression levels of ET-1 and its receptors at different maturation stages, cumulus cells were removed mechanically from each COC before ICSI, transferred individually into tubes containing 200 μl of RNAlater reagent (Ambion), and stored at −80°C until later use. Cultured cumulus cells that had been treated or not with ET-1 were collected to evaluate Cx26 expression. Total RNAs from both cultured and mechanically separated cumulus cells were extracted using the miRNeasy micro kit (Qiagen) and quantitated using a Nanodrop2000 Spectrophotometer (Thermo Scientific). Reverse transcription (RT) was performed using a miScript RT kit (Qiagen). A quantitative polymerase chain reaction (qPCR) assay was performed using a miScript SYBR Green PCR kit (Qiagen) and an ABI 7900HT real-time PCR system (Applied Biosystems). The primers used in the present study are listed in Table I . Dissociation curves were generated to confirm the specificity of amplification. A quantification cycle (Cq) value <37 was considered indicative of expression. Relative mRNA quantification was performed using the comparative Cq method, with the formula 2 -ΔCq and β-actin as the reference gene. The experiments were repeated in triplicate.
Cumulus cell whole-genome transcriptome microarray analyses
The GeneChip ® Human Transcriptome Array 2.0 (Affymetrix) was used to compare the whole-genome transcriptome profiles of cumulus cells from GV-stage COCs that had been cultured in G-IVF medium for 18 h with or without 100 ng/ml ET-1. To improve control, cells were harvested simultaneously. Total RNA isolated from cumulus cells (5 × 10 6 ) was further purified using RNeasy micro kit (QIAGEN). Aliquots of 2 μg total RNA were amplified, labelled and purified using the Affymetrix WT PLUS Reagent Kit (Affymetrix). Array hybridisation and staining were performed according to the manufacturer's instructions. The arrays were scanned using a AffymetrixGeneChip ® Scanner 3000, and raw data were normalised using Expression Console software. The microarray data are published in the GEO database under number GSE97684.
Western blot analysis
To detect Cx26 protein expression, we collected cumulus cells (15 COCs/ treatment) from GV-stage COCs that had been cultured in G-IVF medium for 18 h with or without 100 ng/ml ET-1. Total proteins were extracted using RIPA buffer supplemented with 1% PMSF, separated by SDS-PAGE with a 4% stacking gel and 10% separating gel for 4 h at 60 V, and transferred to polyvinylidene fluoride (PVDF) membranes. After blocking in Tris-buffered saline with Tween-20 (TBST) supplemented with 5% BSA, the membranes were incubated with anti-Cx26 (GJB2) (1:500; Abcam) and anti-GAPDH antibodies (1:500; Abcam) overnight at 4°C. After washing the membranes with TBST, they were incubated with a horseradish peroxidase-conjugated secondary antibody (1:2000; Abcam) for 1 h at room temperature. Immunoreactive bands were then visualised using an enhanced chemiluminescence detection system (Thermo Fisher Scientific). The signal intensity of each immunoreactive brand was analysed using Image J software (Java-based image processing programme; National Institutes of Health).
Immunofluorescence
An immunofluorescence analysis was performed to identify the localisation of ET-1, ETRA, ETRB and Cx26 in oocytes and cumulus cells. GV-stage COCs were fixed with 4% paraformaldehyde for 40 min, followed by treatment with 0.2% Triton X-100 for 20 min. After blocking in PBS containing 1% bovine serum albumin (BSA), the samples were incubated overnight at 4°C with an anti-ET-1 (1:400, abcam), anti-ETRA (1:400, abcam), anti-ETRB (1:400, abcam), or anti-Cx26 antibody (1:400, abcam). After three washes with PBS, the COCs were subsequently incubated with an Alexa Fluor ® 488-conjugated secondary antibody (1:600, abcam) for 1 h at room temperature, and the nuclei were stained with DAPI (2.5 mg/ml). For a negative control, we stained cells with secondary antibody alone to estimate the background signal. Images of the stained cells were acquired with a FV1200 confocal microscope system (Olympus).
Determination of cAMP levels in cumulus cells and oocytes
Cyclic adenosine monophosphate (cAMP) levels were measured in cumulus cell culture supernatants, cumulus cells, and oocytes. Approximately 1 × 10 6 cumulus cells were cultured in α-MEM with or without 100 ng/ml ET-1 for 24 h. Subsequently, 100 μl of culture supernatant was pipetted and stored at −80°C until cAMP levels were assayed. Meanwhile, cumulus cells were washed three times with PBS and lysed with Cell Lysis Buffer for ELISA (Signosis Primer name Sequences (5′−3′)
Cx-26 R AGCCTGGCTGCAGGGTGTTG were cultured with or without 100 ng/ml ET-1 for 24 h. After completely denuding the cumulus cells, the oocytes were frozen in straws at −80°C until further use. A total of 30 treated and untreated oocytes (15 each) were collected and lysed. After subjecting the lysed oocytes and cumulus cells to centrifugation at 12 000g for 5 min, we collected and stored the supernatants at −80°C. An enzyme-linked immunosorbent assay (ELISA) kit (ENZO Life Sciences International) was used to measure cAMP levels according to the manufacturer's instructions.
Statistical analysis
Differences between two groups were evaluated using the t-test or Mann-Whitney U test. Differences among more than two groups were evaluated using an analysis of variance (ANOVA). Comparisons of proportions were made using the χ 2 test and Fisher's exact test. The level of significance was set at a P value <0.05. All data were analysed using Sigmaplot software, version 12.5.
Results
Expression levels of ET-1 and its receptors in cumulus cells at different maturation stages
The expression levels of ET-1, ETRA and ETRB were evaluated in cumulus cells from oocytes at different maturation stages (20 oocytes/group).
As shown in Fig. 1A , the levels of ET-1 in cumulus cells from MI or MII stage oocytes were significantly higher than those in cells from GV-stage oocytes (P < 0.001). However, no differences were observed in the mRNA levels of ET-1 receptors (ETRA and ETRB) among cumulus cells from oocytes at different maturation stages (Fig. 1B and C) . We next evaluated the expression of ET-1 and its receptors on oocytes and cumulus cells from GV-stage COCs and found that ET-1, ETRA and ETRB were expressed in both cell types (Fig. 1D) .
Effect of ET-1 on oocyte maturation and embryonic developmental potential
Previous studies of mouse oocytes have demonstrated that ET-1 promotes oocyte GVBD . Based on these findings, we examined the effect of ET-1 on human oocyte nuclear maturation and evaluated the potential involvement of cumulus cells. As shown in Fig. 2 , for oocytes with cumulus cells, treatment with 100 ng/ml ET-1 significantly increased the GVBD rate from 49.94% ± 1.20% to 68.52% ± 2.73% (P < 0.001). However, for oocytes denuded of cumulus cells, treatment with ET-1 did not affect the GVBD rate (P = 0.583), indicating that ET-1 may regulate human oocyte nuclear maturation through a process mediated by cumulus cells. Although animal studies have not reported any effects of ET-1 on extrusion of the first polar body and cytoplasmic maturation , our study revealed that more oocytes developed to the MII stage when COCs were treated with ET-1, compared with their untreated counterparts (P = 0.008). In addition, oocytes derived from ET-1 treated COCs had a higher normal fertilisation rate (P = 0.041). However, ET-1 treatment during IVM did not affect the rates of embryo cleavage, Day-3 good-quality embryos (defined as embryos with 6-9 cells, <20% fragmentation, equally sized mononucleated blastomeres) or blastocyst formation (Table II) .
Hormone levels in culture supernatants from ET-1 treated cumulus cells
Hormone secretion by ET-1-treated cumulus cells was examined every 9 h. A trend in elevated E 2 levels was observed in culture supernatants after ET-1 treatment. Although the E 2 levels at 18 h and 27 h after ET-1 treatment were significantly higher than the level at 0 h (P < 0.001), the difference between the levels at 18 h and 27 h was not significant (P = 0.812) (Fig. 3A) . The concentrations of FSH and LH remained stable throughout the culture period ( Fig. 3B and C) , and the concentrations of progestogen and testosterone were undetectable in all supernatant samples. Given the importance of E 2 in oocyte maturation (Dumesic et al., 2015) , E 2 secreted by cumulus cells may be involved in ET-1-induced oocyte maturation.
Whole-genome transcriptome analysis of cumulus cells treated with or without ET-1
To explore the downstream effectors through which ET-1 regulates oocyte maturation, we performed a microarray assay to compare the transcriptomes of cultured cumulus cells treated with or without ET-1. A microarray analysis revealed 25 significantly differentially regulated genes (i.e. three-fold change or greater) in cumulus cells, of which 11 were upregulated and 14 were downregulated after ET-1 treatment (Fig. 4A ). Among them, gap junction protein beta 2 (GJB2) was the most significantly downregulated gene. In humans, GJB2 encodes connexin 26 (Cx26), a member of the gap junction protein family. An immunofluorescence assay revealed the expression of Cx26 protein in both cumulus cells and oocytes (Fig. 4B) . RT-qPCR confirmed the results of the microarray analysis; namely, that expression of Cx26 was significantly downregulated in cumulus cells after ET-1 treatment (P = 0.032) (Fig. 4C) . Western blotting revealed that Cx26 protein expression was also downregulated after 12 h of ET-1 treatment (Fig. 4D) .
Effect of ET-1 receptor blockage on Cx26 expression levels in cumulus cells
In cultured cumulus cells, co-treatment with ETRB antagonist BQ-788, but not with the ETRA antagonist BQ-123, blocked the inhibitory effect of ET-1 on Cx26 expression (Fig. 5) . These data indicate that the effect of ET-1 on Cx26 downregulation in cumulus cells is mediated by ETRB.
Concentrations of cAMP in cumulus cells and oocytes treated or untreated with ET-1
GVBD is known to depend on a reduction in the intra-oocyte levels of cAMP (Dumesic et al., 2015) . In cumulus cells, cAMP levels increased significantly after ET-1 treatment (P < 0.001), as shown in Fig. 6A , whereas treatment of these cells with BQ-123 and BQ-788 to block the endothelin-1 receptors led to significant decreases in cAMP levels (P < 0.001). Meanwhile, the cAMP levels in cumulus cell culture Figure 2 The germinal vesicle breakdown (GVBD) rates in cumulus-oocyte complexes (COCs) after endothelin 1 (ET-1) treatment. Black bars indicate treatment with 100 ng/ml ET-1. Grey bars indicate untreated samples. Data are presented as mean percentages (means ± standard errors of the means) of three independent experiments. Each group contained 70 oocytes (n = 70). *P < 0.05. The GVBD rates corresponding to each bar from left to right were 68.52% ± 2.73%, 49.94% ± 1.20%, 42.66% ± 2.66% and 44.30% ± 0.59%, respectively. supernatants decreased significantly after ET-1 treatment (P = 0.024), but exhibited an increasing but non-significant trend when BQ-123 and BQ-788 were added to the cultures. The above experiments led us to determine that ET-1 treatment promotes cAMP accumulation in cumulus cells while decreasing the levels of cAMP in the external culture environment. In a further study of the link between ET-1 and cAMP levels, we observed significantly lower cAMP levels in oocytes derived from COCs treated with ET-1, compared with their untreated counterparts (P = 0.002), whereas culture with BQ-123 and BQ-788 reversed the effects of ET-1 and significantly increased cAMP levels in these cells (P = 0.005) (Fig. 6B ). These data suggest that ET-1 may play a role in the reduction of intra-oocyte cAMP levels and subsequent induction of GVBD.
Discussion
This study demonstrates that ET-1, when added to culture medium, enhances human GV-stage oocyte maturation in vitro. Furthermore, we observed a significant downregulation of the gap junction protein Cx26 in cumulus cells after ET-1 treatment, although this inhibitory effect on Cx26 expression was blocked by co-treatment with an ETRB antagonist. These results suggest that ET-1 regulates human oocyte maturation by downregulating Cx26 expression in cumulus cells via ETRB. Our findings thus update and expand our understanding of the roles of ET-1 and its receptor in the regulation of human oocyte maturation.
In our daily work, we observe that roughly 5-15% of retrieved oocytes are immature, and most of these remain at the GV stage. The ability to culture these immature oocytes to the MII stage would provide an infertile couple with additional opportunities. However, the spontaneous maturation rate of GV oocytes from stimulated cycles is quite low (Ben-Ami et al., 2011) , and an ideal maturation rate cannot be achieved even when gonadotrophins are added to the maturation medium (Chian et al., 2004) . Therefore, it is important to improve the immature oocyte maturation rate and the developmental potential of oocytes matured in vitro.
Ovarian paracrine factors play well-known and critical roles in the regulation of oocyte maturation. Several paracrine factors, such as EGF-like ligands, leptin, brain-derived neurotrophic factor (BDNF) and glial-cell-line-derived neurotrophic factor (GDNF), have been shown to regulate the resumption of meiosis in mammalian oocytes (Park et al., 2004; Kawamura et al., 2005 Kawamura et al., , 2008 Ye et al., 2009) , and some factors, such as BDNF and leptin, promote not only nuclear maturation but also cytoplasmic maturation in oocytes to promote optimal development into blastocysts (Kawamura et al., 2005; Ye et al., 2009) . These findings shed light on a possible strategy for improving the efficiency of human oocyte IVM. Notably, previous reports have described the beneficial effects of BDNF, GDNF and EGF-like ligands on human oocyte maturation when added to the culture media (BenAmi et al., 2011; Zhao et al., 2011) . Our previous study revealed a paracrine role for ET-1 in the induction of mouse oocyte GVBD ( Kawamura et al., 2009) . In the present study, we demonstrated that ET-1 promotes the in-vitro maturation of human GV-stage oocytes. The finding that ET-1 could only induce GVBD in human COCs, but not in denuded oocytes, suggests that ET-1 acts on cumulus cells to regulate human oocyte maturation, similar to the results of our mouse study . Although the animal study did not observe any effects of ET-1 on extrusion of the first polar body and oocyte cytoplasmic maturation (i.e. development into two-cell or blastocyst-stage embryos) , our current study demonstrated that ET-1 treatment induced the development of more oocytes to the MII stage, and we observed a higher normal fertilisation rate among oocytes derived from ET-1 treated COCs. The discrepancies between the human and animal studies may be partly due to differences in species and culture conditions. In the current study, we also observed that ET-1 promoted the secretion of E 2 from cumulus cells. This hormone is crucial for oocyte development, as immature human oocytes employ E 2 -dependent, calcium-mediated mechanisms of cytoplasmic maturation (Tesarik and Mendoza, 1997; Dumesic et al., 2015) . Therefore, the addition of ET-1 to culture medium may improve the developmental potential of oocytes matured in vitro by stimulating E 2 secretion in cumulus cells.
To further investigate the mechanisms by which ET-1-induces human oocyte maturation, we performed whole-genome transcriptome microarray analyses of cumulus cells and identified the significant downregulation of a gap junction protein, Cx26, after ET-1 treatment. Connexins comprise a family of~20 proteins that form intercellular membrane channels and thus provide direct intercellular routes for the passage of metabolites and signalling molecules (Winterhager and Kidder, 2015) . Several connexins, including Cx26, Cx32, Cx37, Cx43 and Cx45, are known to be required for female reproductive functions (Winterhager and Kidder, 2015) . Importantly, during gonadotropininduced ovulation at mid-cycle, the downregulation of connexins parallels meiotic resumption in the oocyte (Eppig, 1982; Larsen et al., 1986) . Cx43 is the most abundant connexin in the follicles, where it contributes to the gap junctions between granulosa cells of growing follicles, while Cx37 is responsible for linking oocytes and cumulus cells. Both Cx43 and Cx37 are required for meiotic arrest (Richard and Baltz, 2014) . However, we did not observe any changes in the Cx43 and Cx37 levels of cumulus cells after ET-1 treatment in the present study, suggesting that ET-1 may initiate the resumption of meiosis via other gap junctions. Cx26 (GJB2), the mutation of which is a common cause of congenital non-syndromic deafness (Dobrowolski and Willecke, 2009) , has been detected in bovine (Berisha et al., 2009) , ovine (Borowczyk et al., 2006) , and human ovarian follicles (Wang et al., 2009) . Cx26 expression increases rapidly in the bovine follicle at 4 h after GnRH injection (during the LH surge) and subsequently decreases, suggesting that this connexin is involved in local cellular mechanisms during the critical time around peri-ovulation (Berisha et al., 2009) . However, the role of Cx26 in the resumption of meiosis has not previously been investigated.
The maintenance of meiosis arrest is well known to depend on a high level of cAMP within the mammalian oocyte (Dekel, 2005) . These intra-oocyte levels of cAMP are regulated by a combination of mechanisms (Campen et al., 2016) . Although oocyte is capable of selfgenerating cAMP, this secondary messenger is also produced within cumulus cells and subsequently transferred to oocytes. LH terminates the flux in follicle cAMP to the oocyte to initiate the resumption of meiosis (Dekel, 2005; Edry et al., 2006) . Here, we found that after ET-1 treatment, cAMP levels were decreased in both oocytes and cumulus cell culture supernatants but were increased in cumulus cells. As ET-1 treatment downregulated Cx26 expression in cumulus cells, our findings suggest that ET-1 may reduce the transfer of cAMP from cumulus cells to oocytes via Cx26 to induce oocyte maturation. Previous studies have suggested that LH-induced EGF-like factors reduce the transfer of cyclic guanosine monophosphate (cGMP) from cumulus cells to oocytes via gap junctions. cGMP inhibits the hydrolytic degradation of cAMP by competitively binding to the catalytic site of phosphodiesterase 3 A (Solc et al., 2010; Conti et al., 2012) . Taken together, these studies suggest that mammalian oocyte maturation is regulated by a complex network of multiple factors and signals within the ovarian follicle.
To the best of our knowledge, the present study demonstrates for the first time that ET-1 can promote the maturation of human GVstage oocytes in vitro. Abnormal ET-1 expression has been reported in granulosa cells from patients with polycystic ovary syndrome (PCOS) (Imbar et al., 2012) . Although these patients characteristically produce increased numbers of oocytes, these are often of poor quality (Qiao and Feng, 2011) . The elucidation of the role of ET-1 in oocyte maturation may also lead to the development of new clinical approaches to the treatment of PCOS.
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